Patents by Inventor Yi-lan Weng

Yi-lan Weng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230346947
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Application
    Filed: November 15, 2022
    Publication date: November 2, 2023
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Patent number: 11497812
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: November 15, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Publication number: 20210205460
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Application
    Filed: August 3, 2020
    Publication date: July 8, 2021
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Patent number: 10898550
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: January 26, 2021
    Assignees: CASE WESTERN RESERVE UNIVERSITY, VERSITECH LIMITED
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
  • Patent number: 10729777
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: August 4, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Publication number: 20200000888
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Application
    Filed: April 11, 2019
    Publication date: January 2, 2020
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
  • Patent number: 10258672
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 16, 2019
    Assignees: CASE WESTERN RESERVE UNIVERSITY, THE UNIVERSITY OF HONG KONG
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng, Heng Li, Wutian Wu
  • Publication number: 20180228905
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-Lan Weng
  • Patent number: 9937242
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: April 10, 2018
    Assignee: Case Western Reserve University
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-lan Weng
  • Publication number: 20170072026
    Abstract: A method of treating root avulsion injury in a subject in need thereof includes administering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of PTP?.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 16, 2017
    Inventors: Jerry Silver, Bradley T. Lang, Jared M. Cregg, Yi-Lan Weng
  • Publication number: 20150366949
    Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
    Type: Application
    Filed: April 9, 2013
    Publication date: December 24, 2015
    Inventors: Bradley T. Lang, Jared M. Cregg, Jerry Silver, Yi-lan Weng